Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate OmniAb, Inc. before investing.

In this article, we go over a few key elements for understanding OmniAb, Inc.’s stock price such as:

• OmniAb, Inc.’s current stock price and volume
• Why OmniAb, Inc.’s stock price changed recently
• Upgrades and downgrades for OABI from analysts
• OABI’s stock price momentum as measured by its relative strength

About OmniAb, Inc. (OABI)

Before we jump into OmniAb, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb’s antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Want to learn more about OmniAb, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about OmniAb, Inc..

OmniAb, Inc.’s Stock Price as of Market Close

As of August 21, 2026, 4:00 PM, CST, OmniAb, Inc.’s stock price was $4.330.

OmniAb, Inc. is up 0.7% from its previous closing price of $4.300.

During the last market session, OmniAb, Inc.’s stock traded between $4.140 and $4.540. Currently, there are approximately 128.80 million shares outstanding for OmniAb, Inc..

OmniAb, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

OmniAb, Inc. Stock Price History

OmniAb, Inc.’s (OABI) price is currently up 118.69% so far this month.

During the month of August, OmniAb, Inc.’s stock price has reached a high of $4.590 and a low of $1.940.

Over the last year, OmniAb, Inc. has hit prices as high as $4.590 and as low as $1.300. Year to date, OmniAb, Inc.’s stock is up 134.05%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused OmniAb, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of August 21, 2026, there were 0 analysts who downgraded OmniAb, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate OmniAb, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on OmniAb, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

OmniAb, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about OmniAb, Inc. (OABI) by visiting AAII Stock Evaluator.

Relative Price Strength of OmniAb, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of August 21, 2026, OmniAb, Inc. has a weighted four-quarter relative price strength of 29.73%, which translates to a Momentum Score of 96 and is considered to be Very Strong.

Want to learn more about how OmniAb, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

OmniAb, Inc. Stock Price: Bottom Line

As of August 21, 2026, OmniAb, Inc.’s stock price is $4.330, which is up 0.7% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like OmniAb, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.